Navigation Links
MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
Date:1/30/2008

ization of anti-infective drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The Company is developing anti-infective drugs based on its novel biological finding that bacteria exposed to antibiotics in front- loaded staccato bursts, or "pulses," are killed more efficiently and effectively than those under standard treatment regimens. Based on this finding, MiddleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(TM). The Company currently markets the Keflex(R) brand of cephalexin and has received regulatory approval for MOXATAG(TM) -- the first and only once-daily amoxicillin product approved for marketing in the U.S. For more on MiddleBrook, please visit http://www.middlebrookpharma.com.

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on MiddleBrook's current expectations and assumptions. These statements are not guarantees of future performance and are subject to a number of risks and uncertainties that would cause actual results to differ materially from those anticipated. The words, "believe," "expect," "intend," "anticipate," and variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward- looking. Statements in this announcement that are forward-looking include, but are not limited to, statements about the Company's future development plans, clinical trials, potential commercial success, and any financial forecasts included in this announcement.

The actual results realized by MiddleBrook could differ materially from these forward-looking statements, depending in particular upon the risks and uncertainties described in the Company's fil
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
2. Access Pharmaceuticals Announces $2.7 Million New Equity
3. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
4. Alexion Pharmaceuticals Invites You to Participate in its Fourth Quarter and Full Year 2007 Results Conference Call and Web Cast
5. Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
6. Onyx Pharmaceuticals to Present at Wachovia Healthcare Conference
7. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
8. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
9. VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
10. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
11. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... (PRWEB) October 22, 2014 Physicians ... its cardiovascular pharmacogenetics menu, which enables healthcare providers ... With PCLS’s evidence-based results, healthcare providers are ... optimize their therapy, while minimizing risks for adverse ... U.S., according to the FDA [1] more than ...
(Date:10/22/2014)... VANCOUVER , Oct. 22, 2014 /PRNewswire/ - iCo ... ICOTF), today announced next steps for its Oral ... findings from its in vitro work ... therapy.  iCo now plans to complete pre clinical ... an initial Phase 1A clinical trial, utilizing approximately ...
(Date:10/22/2014)... and HONG KONG , Oct. ... disease therapeutics enterprise, announced today that rare disease expert ... as vice president, research. Dr. McKew brings more than ... leadership positions at the National Institutes of Health, Wyeth ... by Wyeth). Dr. McKew will lead aTyr,s efforts to expand ...
(Date:10/20/2014)... October 20, 2014 Convey Computer ... a team from Iowa State University won first place ... Using a Convey HC-2ex, the team’s solution achieved the ... faster than the second place finisher. , Experts from ... upon the month long challenge, using a variety of ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3
... Phosphatase useful for dephosphorylation serine,threonine or tyrosine ... Mary Ellen Simcox ,Stratagene Cloning Systems, Inc. ... dualspecificity protein,phosphatase that has been produced as ... calmodulinbinding peptide. The tag simplifies purification of ...
... polymerase delivers high fidelity and great,performance ... Holly Hogrefe ,Stratagene , Stratagene has ... novel enzyme formulation that provides,superior performance in ... that Herculase enhanced DNA polymerase is even ...
... Generate cDNA libraries with as little as 50 ng ... Tanya Hosfield ,Marie Callahan ,John C. Bauer Mike ... Lenhart Paul Young ,Human Genome Sciences, Rockville, Maryland , ... new method to generate high-efficiency cDNA libraries in a plasmid,vector. ...
Cached Biology Technology:Highly Active and Removable AffinityTagged Lambda Phosphatase 2Highly Active and Removable AffinityTagged Lambda Phosphatase 3Highly Active and Removable AffinityTagged Lambda Phosphatase 4Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 2Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 3Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 4Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 5Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 6Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 7Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 8Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 9Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 10Constructing Directional cDNA Libraries from Limited Amounts of RNA 2Constructing Directional cDNA Libraries from Limited Amounts of RNA 3Constructing Directional cDNA Libraries from Limited Amounts of RNA 4Constructing Directional cDNA Libraries from Limited Amounts of RNA 5Constructing Directional cDNA Libraries from Limited Amounts of RNA 6Constructing Directional cDNA Libraries from Limited Amounts of RNA 7
(Date:10/18/2014)... 2,000 patients referred for evaluation of suspected genetic ... for 25 percent, including detection of a number ... to disease, according to a study appearing in ... to coincide with the American Society of Human ... exons or coding regions of thousands of genes ...
(Date:10/17/2014)... knowledge regarding Ebola is critical and pertinent for practicing ... global outbreak and epidemic. The Journal, Disaster Medicine ... issue, Ebola Virus and Public Health, to surround the ... this critical societal moment. , On October 17, ... Clinicians . The primer was prepared by Dr. Eric ...
(Date:10/17/2014)... of Copenhagen have shown for the first time how ... fibrosis patients, giving them the opportunity to get tremendous ... , The study also discovered the bacterial growth in ... halted or slowed down by the immune cells. The ... and helped "suffocate" the bacteria, forcing the bacteria to ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2
... MADISON, WI, MARCH 1, 2011 Methane ... permafrost, termites, oceans, freshwater bodies, non-wetland soils, are all ... methane presence ca n be accredited to human-related activities. ... burning, waste management and animal husbandry. The release of ...
... available in Spanish . , Those who ... and teas may tend to overlook the benefits of drinking ... Agricultural Research magazine, the idea that herbal teas may provide ... U.S. Department of Agriculture (USDA)-funded scientists in Boston, Mass., ...
... release is available in Spanish . ... (UPV/EHU), has developed genetic-molecular tools, with the intention of completing ... equine breeds in the Basque Country Autonomous Community (CAPVEAE) and ... DNA sequence) and certain SNPs (a kind of variation in ...
Cached Biology News:Measuring methane 2Don't underestimate the power of herbal teas 2Basque thesis investigates wide diversity within certain ovine, bovine and equine breeds 2Basque thesis investigates wide diversity within certain ovine, bovine and equine breeds 3
MOUSE ANTI HUMAN NPM...
MOUSE ANTI PROTEIN KINASE C BETA 2 Immunogen: Protein kinase C beta 2...
Antibodies were affinity purified using epitopes specific to JLP immobilized on solid support....
... et.al. (1997) • Contains short ... biochemistry & molecular biology, arranged ... Entries give details of biochemical ... which they are involved and ...
Biology Products: